Left atrial appendage occlusion
Ask the expert
The report presents a summary of reimbursement situation for left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe.
Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).
The following types of procedure will be considered:
- percutaneous transluminal left atrial appendage occlusion;
- thoracoscopic left atrial appendage closure.
The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of treatment of left appendage occlusion:
- Abbott Laboratories (Amplatzer Amulet)
- Aegis Medical (Sierra)
- Atricure (AtriClip)
- Biosense Webster (WaveCrest)
- Boston Scientific (WATCHMAN)
- Cardia (Ultrasept)
- Lifetech Scientific (LAmbre)
- Sentreheart (LARIAT)
Table of content is not available at the moment. Report is still ongoing.
In Q1 of 2022, Health Technology Wales (HTW) published one MedTech-related guidance on transcranial magnetic stimulation in depression treatment. A total of eleven Topic Exploration Reports (TERs) were released in Q1. Based on the TERs conclusions, HTW's Assessment Group decided to proceed with developing an Evidence Appraisal Report (EAR) and Guidance on one topic only - radiofrequency renal denervation for the treatment of resistant hypertension.Read more
On June 18, 2020, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced four medical procedures which received a subsidy under the new innovative payment scheme: FFRct technique in the diagnosis of patients with chest pain; oral esketamine in patients with severe, non-psychotic, treatment-resistant depression; left atrial appendage closure in patients with atrial fibrillation and endolymphatic duct blockage in patients with uncontrollable Meniere's disease.Read more
In February 2020, the Andalusian Health Technology Assessment Department published an assessment report on the evaluation of effectiveness and safety of epicardial closure of left atrial appendage using clips by minimally invasive surgery for thromboembolism prevention in patients with atrial fibrillation. The scientific evidence about the effectiveness and safety of the left atrial appendage closure through minimally invasive epicardial clipping is inadequate and insufficient; further research is needed.Read more
In early September 2019, the Innovation Committee of the Federal Joint Committee (G-BA) has published an overview of new research projects in the area of health services to be funded by the Innovation Fund in the future.Read more
The report presents a summary of reimbursement situation for left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe. The following types of procedure will be considered: percutaneous transluminal left atrial appendage occlusion; thoracoscopic left atrial appendage closure. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.Read more